全文获取类型
收费全文 | 2236篇 |
免费 | 379篇 |
国内免费 | 61篇 |
专业分类
电工技术 | 8篇 |
综合类 | 31篇 |
化学工业 | 1895篇 |
金属工艺 | 171篇 |
机械仪表 | 14篇 |
建筑科学 | 15篇 |
矿业工程 | 26篇 |
能源动力 | 24篇 |
轻工业 | 258篇 |
水利工程 | 3篇 |
石油天然气 | 55篇 |
无线电 | 13篇 |
一般工业技术 | 50篇 |
冶金工业 | 32篇 |
原子能技术 | 11篇 |
自动化技术 | 70篇 |
出版年
2024年 | 2篇 |
2023年 | 42篇 |
2022年 | 48篇 |
2021年 | 270篇 |
2020年 | 99篇 |
2019年 | 102篇 |
2018年 | 99篇 |
2017年 | 73篇 |
2016年 | 121篇 |
2015年 | 123篇 |
2014年 | 138篇 |
2013年 | 186篇 |
2012年 | 163篇 |
2011年 | 164篇 |
2010年 | 133篇 |
2009年 | 165篇 |
2008年 | 113篇 |
2007年 | 104篇 |
2006年 | 102篇 |
2005年 | 64篇 |
2004年 | 63篇 |
2003年 | 56篇 |
2002年 | 44篇 |
2001年 | 37篇 |
2000年 | 22篇 |
1999年 | 12篇 |
1998年 | 11篇 |
1997年 | 12篇 |
1996年 | 6篇 |
1995年 | 14篇 |
1994年 | 14篇 |
1993年 | 9篇 |
1992年 | 14篇 |
1991年 | 6篇 |
1990年 | 6篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 8篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有2676条查询结果,搜索用时 31 毫秒
21.
Dr. Lilia Clima Bogdan Florin Craciun Dr. Andrea Angeli Andrea Petreni Alessandro Bonardi Dr. Alessio Nocentini Dr. Fabrizio Carta Prof. Paola Gratteri Prof. Mariana Pinteala Prof. Claudiu T. Supuran 《ChemMedChem》2020,15(21):2052-2057
We report novel molecules incorporating the nontoxic squalene scaffold and different carbonic anhydrase inhibitors (CAIs). Potent inhibitory action, in the low-nanomolar range, was detected against isoforms hCA II for sulfonamide derivatives, which proved to be selective against this isoform over the tumor-associate hCA IX and XII isoforms. On the other hand, coumarin derivatives showed weak potency but high selectivity against the tumor-associated isoform CA IX. These compounds are interesting candidates for preclinical evaluation in glaucoma or various tumors in which the two enzymes are involved. In addition, an in silico study of inhibitor-bound hCA II revealed extensive interactions with the hydrophobic pocket of the active site and provided molecular insights into the binding properties of these new inhibitors. 相似文献
22.
23.
Pavlína Janovsk Emmanuel Normant Hari Miskin Vítzslav Bryja 《International journal of molecular sciences》2020,21(23)
The casein kinase 1 enzymes (CK1) form a family of serine/threonine kinases with seven CK1 isoforms identified in humans. The most important substrates of CK1 kinases are proteins that act in the regulatory nodes essential for tumorigenesis of hematological malignancies. Among those, the most important are the functions of CK1s in the regulation of Wnt pathways, cell proliferation, apoptosis and autophagy. In this review we summarize the recent developments in the understanding of biology and therapeutic potential of the inhibition of CK1 isoforms in the pathogenesis of chronic lymphocytic leukemia (CLL), other non-Hodgkin lymphomas (NHL), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and multiple myeloma (MM). CK1δ/ε inhibitors block CLL development in preclinical models via inhibition of WNT-5A/ROR1-driven non-canonical Wnt pathway. While no selective CK1 inhibitors have reached clinical stage to date, one dual PI3Kδ and CK1ε inhibitor, umbralisib, is currently in clinical trials for CLL and NHL patients. In MDS, AML and MM, inhibition of CK1α, acting via activation of p53 pathway, showed promising preclinical activities and the first CK1α inhibitor has now entered the clinical trials. 相似文献
24.
Amila Turalić Prof. Jasmina Đeđibegović Dr. Zsófia Hegedüs Prof. Tamás A. Martinek 《Chembiochem : a European journal of chemical biology》2020,21(14):2060-2066
The incorporation of β-amino acids into a peptide sequence has gained particular attention as β- and α/β-peptides have shown remarkable proteolytic stability, even after a single homologation at the scissile bond. Several peptidases have been shown to cleave such bonds with high specificity but at a much slower rate compared to α-peptide bonds. In this study, a series of analogs of dipeptidyl peptidase-4 (DPP-4) substrate inhibitors were synthesized in order to investigate whether β-amino acid homologation at the scissile bond could be a valid approach to improving peptide stability towards DPP-4 degradation. DPP-4 cleaved the α/β-peptide bond after the N-terminal penultimate Pro with a broad specificity and retained full activity regardless of the β3-amino acid side chain and peptide length. Significantly improved half-lives were observed for β3Ile-containing peptides. Replacing the penultimate Pro with a conformationally constrained Pro mimetic led to proteolytic resistance. DPP-4 cleavage of α/β-peptide bonds with a broad promiscuity represents a new insight into the stability of peptide analogs containing β-amino acids as such analogs were thought to be stable towards enzymatic degradation. 相似文献
25.
Federica Bovio Samantha Epistolio Alessandra Mozzi Eugenio Monti Paola Fusi Matilde Forcella Milo Frattini 《International journal of molecular sciences》2020,21(22)
The epidermal growth factor receptor (EGFR), through the MAP kinase and PI3K-Akt-mTOR axis, plays a pivotal role in colorectal cancer (CRC) pathogenesis. The membrane-associated NEU3 sialidase interacts with and desialylates EGFR by promoting its dimerization and downstream effectors’ activation. Among the targeted therapies against EGFR, the monoclonal antibody cetuximab is active only in a subgroup of patients not carrying mutations in the MAP kinase pathway. In order to better understand the EGFR-NEU3 interplay and the mechanisms of pharmacological resistance, we investigated the role of NEU3 deregulation in cetuximab-treated CRC cell lines transiently transfected with NEU3 using Western blot analysis. Our results indicate that NEU3 overexpression can enhance EGFR activation only if EGFR is overexpressed, indicating the existence of a threshold for NEU3-mediated EGFR activation. This enhancement mainly leads to the constitutive activation of the MAP kinase pathway. Consequently, we suggest that the evaluation of NEU3 expression cannot entirely substitute the evaluation of EGFR because EGFR-negative cases cannot be stimulated by NEU3. Furthermore, NEU3-mediated hyperactivation of EGFR is counterbalanced by the administration of cetuximab, hypothesizing that a combined treatment of NEU3- and EGFR-targeted therapies may represent a valid option for CRC patients, which must be investigated in the future. 相似文献
26.
Dr. Yahu A. Liu Dr. Qihui Jin Qiang Ding Dr. Xueshi Hao Tingting Mo Shanshan Yan Dr. Yefen Zou Dr. Zhihong Huang Xiaoyue Zhang Wenqi Gao Dr. Tom Y.-H. Wu Chun Li Dr. Badry Bursalaya Dr. Michael Di Donato Dr. You-Qing Zhang Lisa Deaton Dr. Weijun Shen Dr. Brandon Taylor Anwesh Kamireddy Dr. George Harb Dr. Jing Li Dr. Yong Jia Dr. Andrew M. Schumacher Dr. Bryan Laffitte Dr. Richard Glynne Dr. Shifeng Pan Dr. Peter McNamara Dr. Valentina Molteni Dr. Jon Loren 《ChemMedChem》2020,15(16):1562-1570
Loss of β-cell mass and function can lead to insufficient insulin levels and ultimately to hyperglycemia and diabetes mellitus. The mainstream treatment approach involves regulation of insulin levels; however, approaches intended to increase β-cell mass are less developed. Promoting β-cell proliferation with low-molecular-weight inhibitors of dual-specificity tyrosine-regulated kinase 1A (DYRK1A) offers the potential to treat diabetes with oral therapies by restoring β-cell mass, insulin content and glycemic control. GNF4877, a potent dual inhibitor of DYRK1A and glycogen synthase kinase 3β (GSK3β) was previously reported to induce primary human β-cell proliferation in vitro and in vivo. Herein, we describe the lead optimization that lead to the identification of GNF4877 from an aminopyrazine hit identified in a phenotypic high-throughput screening campaign measuring β-cell proliferation. 相似文献
27.
Tobias E. Schmitzhaus Maria R. Ortega Vega Roberto Schroeder Iduvirges L. Muller Silvana Mattedi Célia de Fraga Malfatti 《工业材料与腐蚀》2020,71(11):1885-1902
The aim of the present study is to evaluate the performance of N-methyl-2-hydroxyethylammonium oleate ([m-2HEA][Ol]) as a corrosion inhibitor for mild steel in a 0.1-mol/L hydrochloric acid solution and also investigate the role of chloride in the inhibition mechanism. This protic ionic liquid (PIL) has formerly shown a high efficiency as a corrosion inhibitor in a neutral chloride medium. Electrochemical and weight loss measurements, surface contact angle determination, scanning electron microscopy, and Raman spectroscopy were used to understand the factors that influence the response of the studied inhibitor. Results revealed that [m-2HEA][Ol] behaves as a mixed-type adsorption inhibitor, by blocking cathodic sites and by modifying the activation energy of the anodic reaction, and it can reach up to 94–97% of inhibition efficiency. PIL adsorption was enhanced by the excess of positive charge of the mild steel. The effect of inhibitor molecule has been discussed to propose a mechanism that explains the inhibitory action of the corrosion inhibitor, pointing out the role of chloride in the inhibition mechanism. 相似文献
28.
29.
Agnieszka Rybarczyk-Kasiuchnicz Rodryg Ramlau Katarzyna Stencel 《International journal of molecular sciences》2021,22(2)
Lung cancer is one of the most common malignant neoplasms. As a result of the disease’s progression, patients may develop metastases to the central nervous system. The prognosis in this location is unfavorable; untreated metastatic lesions may lead to death within one to two months. Existing therapies—neurosurgery and radiation therapy—do not improve the prognosis for every patient. The discovery of Epidermal Growth Factor Receptor (EGFR)—activating mutations and Anaplastic Lymphoma Kinase (ALK) rearrangements in patients with non-small cell lung adenocarcinoma has allowed for the introduction of small-molecule tyrosine kinase inhibitors to the treatment of advanced-stage patients. The Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein with tyrosine kinase-dependent activity. EGFR is present in membranes of all epithelial cells. In physiological conditions, it plays an important role in the process of cell growth and proliferation. Binding the ligand to the EGFR causes its dimerization and the activation of the intracellular signaling cascade. Signal transduction involves the activation of MAPK, AKT, and JNK, resulting in DNA synthesis and cell proliferation. In cancer cells, binding the ligand to the EGFR also leads to its dimerization and transduction of the signal to the cell interior. It has been demonstrated that activating mutations in the gene for EGFR-exon19 (deletion), L858R point mutation in exon 21, and mutation in exon 20 results in cancer cell proliferation. Continuous stimulation of the receptor inhibits apoptosis, stimulates invasion, intensifies angiogenesis, and facilitates the formation of distant metastases. As a consequence, the cancer progresses. These activating gene mutations for the EGFR are present in 10–20% of lung adenocarcinomas. Approximately 3–7% of patients with lung adenocarcinoma have the echinoderm microtubule-associated protein-like 4 (EML4)/ALK fusion gene. The fusion of the two genes EML4 and ALK results in a fusion gene that activates the intracellular signaling pathway, stimulates the proliferation of tumor cells, and inhibits apoptosis. A new group of drugs—small-molecule tyrosine kinase inhibitors—has been developed; the first generation includes gefitinib and erlotinib and the ALK inhibitor crizotinib. These drugs reversibly block the EGFR by stopping the signal transmission to the cell. The second-generation tyrosine kinase inhibitor (TKI) afatinib or ALK inhibitor alectinib block the receptor irreversibly. Clinical trials with TKI in patients with non-small cell lung adenocarcinoma with central nervous system (CNS) metastases have shown prolonged, progression-free survival, a high percentage of objective responses, and improved quality of life. Resistance to treatment with this group of drugs emerging during TKI therapy is the basis for the detection of resistance mutations. The T790M mutation, present in exon 20 of the EGFR gene, is detected in patients treated with first- and second-generation TKI and is overcome by Osimertinib, a third-generation TKI. The I117N resistance mutation in patients with the ALK mutation treated with alectinib is overcome by ceritinib. In this way, sequential therapy ensures the continuity of treatment. In patients with CNS metastases, attempts are made to simultaneously administer radiation therapy and tyrosine kinase inhibitors. Patients with lung adenocarcinoma with CNS metastases, without activating EGFR mutation and without ALK rearrangement, benefit from immunotherapy. This therapeutic option blocks the PD-1 receptor on the surface of T or B lymphocytes or PD-L1 located on cancer cells with an applicable antibody. Based on clinical trials, pembrolizumab and all antibodies are included in the treatment of non-small cell lung carcinoma with CNS metastases. 相似文献
30.